Skip to main content

Table 3 Cox regression analysis to assess hospital admissions/emergency department visits

From: Factors influencing hospitalization or emergency department visits and mortality in type 2 diabetes following the onset of new cardiovascular diagnoses in a population-based study

  

Hazard

95.0% CI for HR

p-value

  

ratio

Lower

Upper

 

Diagnose origin

     

IPC

Reference

1.00

   

OPC

 

0.89

0.68

1.16

0.06

Primary care

 

0.52

0.35

0.77

< 0.001

Emergency department

 

1.23

0.78

1.94

0.80

Sex and age

     

Women

 

0.88

0.72

1.07

0.20

Age

 

1.02

1.00

1.03

0.01

Systolic blood pressure

     

< 100 mm Hg

Reference

1.00

   

100–130 mmHg

 

0.61

0.32

1.14

0.31

> 130 mm Hg

 

0.54

0.29

1.00

0.21

Renal function

     

eGFR > 60 ml/min

Reference

1.00

   

eGFR 30–60 ml/min

 

0.87

0.69

1.09

0.30

eGFR < 30 ml/min

 

0.85

0.58

1.24

0.40

Glucose regulation

     

HbA1c < 52 mmol/ml

Reference

1.00

   

HbA1c 52–70 mmol/ml

 

0.85

0.69

1.05

0.43

HbA1c > 70 mmol/ml

 

0.76

0.54

1.07

0.90

LDL-cholesterol  2.5 mmol/ml

 

1.00

   

LDL-cholesterol < 2.5 mmol/ml

 

1.05

0.84

1.32

0.67

Pharmacotherapy

     

Insulin

 

1.29

1.04

1.61

0.02

Metformin

 

0.88

0.70

1.10

0.25

DPP4

 

1.38

1.10

1.74

0.006

GLP1

 

1.04

0.78

1.38

0.81

SGLT2

 

1.01

0.77

1.34

0.93

Aldosterone antagonist

 

1.63

1.27

2.08

< 0.001

Betablocker

 

1.34

1.08

1.67

0.008

Calcium blocker

 

1.21

0.99

1.47

0.06

RAASi

 

1.01

0.80

1.26

0.95

Statin

 

0.97

0.71

1.32

0.82

Healthcare utilization

     

Hospital out-patient care visit > 30 days

Reference

1.00

   

Hospital out-patient care visit  30 days

 

2.19

1.70

2.82

< 0.001

Primary care visit > 30 days

Reference

1.00

   

Primary care visit  30 days

 

0.86

0.70

1.05

0.13

  1. Note CI = confidence interval, IPC = in-patient care (hospitalization), OPC = out-patient care in hospital setting, HbA1c = hemoglobin A1c, LDL-cholesterol = Low-density lipoprotein cholesterol, eGFR = estimated glomerulofiltration rate, GLP1 = Glucagon-like peptide-1 agonists, DPP4 = dipeptidyl peptidase 4 inhibitors, SGLT-2 = sodium-glucose cotransporter-2 inhibitors, RAASi = Renin-angiotensin-aldosterone system inhibitors